Hpv-related Cervical Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-05-06
Clinical Trial Update: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) [Phase 2]
Phase 2 immunogenicity and safety study of an 11-valent HPV vaccine completed.